Drug Sponsors

Cerulean reduces workforce

Friday, August 19, 2016

Cerulean Pharma, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), is reducing its workforce by approximately 48%, to a total of 23 full-time equivalent employees, under a plan expected to be substantially completed by the end of 2016. This workforce reduction is designed to reduce operating expenses while the company refocuses its clinical strategy for CRLX101. Affected employees are being offered severance and outplacement assistance.

[Read More]

10 Tips for Enabling Better CRO-Sponsor Collaborations

Thursday, August 18, 2016

By Craig Morgan, brand development director at goBalto Inc.

By 2020[1] 72% of clinical trials are anticipated to be outsourced, up from just 23% in 2012. Sponsors are seeking cost reductions, access to specialized knowledge, and increased speed and agility. Meanwhile, CROs focus is on business goals related to economic outcomes for their owners, investors and shareholders. Each group is expecting deliverables and timelines to be met or exceeded for potentially different business reasons, leading to a traditional client/vendor-type relationship. Though alliances and partnerships are increasing, there continues to be a client/vendor mentality at the operational and management levels, which perpetuates a lack of trust and empowerment.

[Read More]

Allergan to expand in New Jersey, to create 300 jobs

Tuesday, August 16, 2016

The Board of the New Jersey Economic Development Authority (EDA) has approved Grow New Jersey (Grow NJ) tax credits to encourage the global pharmaceutical company Allergan, the U.S. subsidiary of Ireland-based Allergan, to remain in New Jersey and combine four existing company locations into a 431,495-square-foot facility in Madison. 

[Read More]

Mallinckrodt to acquire Stratatech

Monday, August 15, 2016

Mallinckrodt, a global specialty pharmaceutical company, has entered into a merger agreement with Stratatech, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.

[Read More]

Myriad to acquire Assurex Health

Thursday, August 4, 2016

Myriad Genetics, a leader in molecular diagnostics and personalized medicine, has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad’s fiscal year 2016.

[Read More]

BTC Network rebrands, acquires Novex Clinical Research

Tuesday, August 2, 2016

BTC Network, a fully integrated network of clinical research sites in the U.S., has strengthened its site operations with the recent acquisition of Novex Clinical Research, a multi-specialty research practice in New Bedford, Massachusetts. As a result of the deal, Novex Clinical Research will be the first clinical research site to be owned and operated under the BTC Network umbrella. It will strengthen BTC Network’s expertise and commitment to therapeutic areas such as psychiatry, neurology, pain, and internal medicine.

[Read More]